Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
CONGRESS PHARMA from Sint-Pieters-Woluwe, company number BE0743735919, closed financial year 2025 with a result of € -301 after tax. For that financial year CONGRESS PHARMA recorded a gross margin of € 11,546 and equity of € 10,393. Compared with financial year 2024, the result moved from € 7,411 to € -301. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 10,393
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -301
▼ still € 7,411 profit in 2024
Profit after tax over the fiscal year.
€ 42,698
▲ € 34,944 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 10,392.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 72,178
▼ 47% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 247,335 | € 107,282 | € 452 | € 11,546 | ▲ € 11,095 |
| Profit after taxes | € 170,905 | € 2,554 | € 7,411 | € -301 | ▼ € 7,712 |
| Equity | € 729 | € 3,283 | € 10,694 | € 10,393 | ▼ 3% |
| Total debts | € 523,041 | € 120,334 | € 135,406 | € 72,178 | ▼ 47% |
| Cash | € 255,113 | € 10,589 | € 7,754 | € 42,698 | ▲ € 34,944 |
| Retained profit | € 728 | € 3,282 | € 10,693 | € 10,392 | ▼ 3% |
| Balance sheet total | € 523,770 | € 123,616 | € 146,099 | € 82,571 | ▼ 43% |
Key figures of CONGRESS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CONGRESS PHARMA?
What happened at CONGRESS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Xavier Dandoy stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 301 (▼ € 7,712 vs 2024). Source: NBB ↗
- Xavier Dandoy became a director. NBB
- New establishment in Ottignies-Louvain-la-Neuve. KBO
- Start of the company according to the CBE. KBO
In short
From € 170,905 profit in 2022 to € 301 loss in 2025.
Paid € 2,948 in corporate taxes since 2022.
Best year ever: 2022, with € 170,905 profit.
A new publication or filing at CONGRESS PHARMA? We notify you, reason included.
Follow CONGRESS PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
since 2022 · until 2027
Establishments
Establishment units
Physical locations of this company
Tervurenlaan 295
1150 Sint-Pieters-Woluwe
Place de l'Université 16
1348 Ottignies-Louvain-la-Neuve
Active since 1 March 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0743.735.919
- VAT number
- BE 0743.735.919
- Registered office
- Tervurenlaan 295, 1150 Sint-Pieters-Woluwe
- Names & denominations
- CONGRESS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 February 2020
- Peppol
- Not registered
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied